Drug Development After the Sars Epidemic

Scientists responded to the two thousand and three outbreak by designing amoe that inhibits a protein integral to corona virous replication. But infections soon petered out, and after the last cases of sars were reported in two thousand and four, fizer and other companies working on sars drugs shelved their programms. As u n c verologist timothy shehan says, it's hard to convince a company to make a drug against something that doesn't exist.